Non-Hodgkin Lymphoma

FDA Approves Mogamulizumab-kpkc for Rare Subtypes of Non-Hodgkin Lymphoma

FDA Approves Mogamulizumab-kpkc for Rare Subtypes of Non-Hodgkin Lymphoma

By

Mogamulizumab-kpkc (Poteligeo), a humanized monoclonal antibody that targets CCR4, provides a new treatment option for patients with MF and is the first FDA-approved therapy for SS.

Interim PET Scans May Predict Survival Outcomes in Non-Hodgkin Lymphoma

Interim PET Scans May Predict Survival Outcomes in Non-Hodgkin Lymphoma

By

Being able to identify which patients would respond to standard therapies allows for early adjustment in treatment and improves outcomes.

Evaluating the Relationship Between Q Fever and Non-Hodgkin Lymphoma

Evaluating the Relationship Between Q Fever and Non-Hodgkin Lymphoma

By

Findings from a previous study suggested that Q fever may significantly increase a person's risk of nHL.

Obinutuzumab Plus Bendamustine Prolongs PFS in Rituximab-Refractory Non-Hodgkin Lymphoma

Obinutuzumab Plus Bendamustine Prolongs PFS in Rituximab-Refractory Non-Hodgkin Lymphoma

By

Previous findings showed that patients obinutuzumab plus bendamustine prolonged progression-free survival, but data was immature at the time of analysis.

Poorer DLBCL Survival Outcomes Linked to Dual Expression of MYC, BCL2

Poorer DLBCL Survival Outcomes Linked to Dual Expression of MYC, BCL2

By

Dual expression of MYC and BCL2 was associated with worse survival among patients with GCB-like DLBCL, though this status was not associated with any outcomes among patients with ABC-like DLBCL.

In Focus: Bendamustine for Non-Hodgkin Lymphomas

In Focus: Bendamustine for Non-Hodgkin Lymphomas

By

Data support use of bendamustine for patients treated with several lines of therapy, but whether this drug should be used in the first line is open to question.

Periodontal Disease: A Risk Factor for Non-Hodgkin Lymphoma?

Periodontal Disease: A Risk Factor for Non-Hodgkin Lymphoma?

By

More studies are needed to determine the association between periodontal disease and non-Hodgkin lymphoma.

Thirty-month Complete Response in Follicular Lymphoma: A New Endpoint?

Thirty-month Complete Response in Follicular Lymphoma: A New Endpoint?

By

Thirty-month complete response is an accurate predictive endpoint for progression-free survival in follicular lymphoma clinical trials.

Coping With Non-Hodgkin Lymphoma

Coping With Non-Hodgkin Lymphoma

Non-Hodgkin lymphoma (NHL) is a group of cancers affecting cells called lymphocytes in the lymphatic system.

Obinutuzumab Plus Bendamustine Improves Progression-Free Survival in Non-Hodgkin Lymphoma

Obinutuzumab Plus Bendamustine Improves Progression-Free Survival in Non-Hodgkin Lymphoma

By

Obinutuzumab combined with bendamustine improved progression-free survival in rituximab-refractory indolent non-Hodgkin lymphoma (iNHL).

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs